

# CITATION REPORT

List of articles citing

**Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials**

**DOI: 10.1007/s00280-020-04156-3**

**Cancer Chemotherapy and Pharmacology, 2020, 86, 577-588.**

**Source:** <https://exaly.com/paper-pdf/75553029/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. <i>Pharmaceutics</i> , 2021, 13,	6.4	
4	Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 1-7	3.2	0
3	Perspectives toward biosimilars among oncologists: A Malaysian survey. <i>Journal of Oncology Pharmacy Practice</i> , 107815522211047	1.7	0
2	Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
1	Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report. 9,		0